Personalised medicine continues to develop and drive change away from the ‘one size fits all’ delivery of care. The rate of development of healthcare innovation is increasing, as is the cost and the expectations of the public for improvements in NHS services.
Given these developments, and the genomics focus of the AHSN’s personalised medicine work programme, technologies with an ‘omics component were selected for analysis in this report. Each technology presents an opportunity for the AHSN Network to support innovation adoption and spread.
Earlier this year the Academic Health Science Network (AHSN) commissioned the PHG Foundation to produce a report that presents an evidence review of genomics and genomics-related technologies that will have an impact on the delivery of personalised medicine within two to three years or even sooner given the current pace of change arising from the COVID-19 pandemic.
The report builds on the 2018 publication ‘The Personalised Medicine Technology Landscape’ and underpins the AHSN Networks work in delivering a thematic programme on personalised medicine, established to support the implementation of novel diagnostic and treatment approaches that make use of genomics and other ‘omics technologies.
The report was launched today via a webinar, featuring a film that can be viewed here. Tony Davis, WMAHSN Director of Innovation & Economic Growth commissioned the report, wrote the forward, worked on delivering the report, video and webinar and will be responsible for chairing the work group formed for taking the recommendations forward.
In the report's foreword, Tony Davis explains, "By using genomics to understand the most effective mode of care for the individual, we can improve the impact of treatment. Genomics is a step change in personalised medicine, but it should be understood that it is not personalised medicine per se. It should be viewed as part of an innovative personalised medicine toolkit alongside other diagnostics that has now expanded to include a wider family of genomics-related and other ‘omics technologies, such as proteomics, transcriptomics and pharmacogenomics."